This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga • Aug 18, 2026

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 32,900 common shares of the Company (the "Options") with effective grant dates of August 17, 2026.

Business Wire • Aug 17, 2026

Definium Therapeutics' DT120 Meets Phase III Goals in GAD Study

Definium Therapeutics NASDAQ: DFTX reported positive top-line results from Voyage, its Phase III study evaluating a single 100 mcg dose of DT120 ODT for generalized anxiety disorder, or GAD. The company said the trial met its primary endpoint and all key secondary endpoints, showing rapid and durable improvements in anxiety symptoms through 12 weeks.

MarketBeat • Aug 13, 2026

This LSD-Based Drug Just Scored Again. Definium Stock Soars.

Definium Therapeutics unveiled the second of two positive Phase 3 studies for its LSD-based drug. The biotech stock surged on the results.

Investors Business Daily • Aug 12, 2026

Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'

Late-stage clinical biopharmaceutical firm Definium Therapeutics, Inc. (NASDAQ:DFTX) has announced highly encouraging topline data from its Voyage trial.

Benzinga • Aug 12, 2026

Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript

Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript

Seeking Alpha • Aug 12, 2026

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Voyage, its first Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) 100 µg in adults with generalized anxiety disorder (GAD). The results mark the Company's se.

Business Wire • Aug 12, 2026

Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst

Definium Therapeutics remains a 'Strong Buy' following positive phase 3 VOYAGE data for DT120 ODT in generalized anxiety disorder [GAD]. The company's DT120 ODT achieved a statistically significant -5.4 placebo-adjusted reduction in HAM-A score at 12 weeks in GAD, highlighting best-in-class potential. Upcoming catalysts include phase 3 PANORAMA GAD data in September 2026 and ASCEND MDD topline results in 2027.

Seeking Alpha • Aug 12, 2026

Definium Therapeutics Q2 Earnings Call Highlights

Definium Therapeutics NASDAQ: DFTX said it expects to report top-line results from its Phase III VOYAGE study of DT120 ODT in generalized anxiety disorder during the week of Aug. 10, following positive Phase III results in major depressive disorder reported in June.

MarketBeat • Aug 7, 2026

Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript

Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript

Seeking Alpha • Aug 7, 2026